Thoracic, Head & Neck Cancer Protocols

Cancer Protocol& Research

Providing patients and health care professionals access to the on-going clinical trials thatare open for patient enrollment

Thoracic, Head & Neck Cancer Protocols

  • Head and Neck Cancer (ECOG 1305): Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
  • Aranesp (NSCLC): A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 ug Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy

Contact Information

  • Frances D’Allesandro, C.C.R.P. 
    Clinical Research Coordinator, RWMC Protocol Office
    Phone: (401) 456-2698 - Fax: (401) 456-2658 - fdallesandro@chartercare.org
  • Jessica Donaghy A.S.
    Administrative Associate, RWMC Protocol Office 
    Phone: (401) 456-5393 - Fax: (401) 456-2658 - jdonaghy@chartercare.org
  • 825 Chalkstone Avenue, Providence, Rhode Island 02908
  • 401-456-2000

© 2011 CharterCARE Health Partners